BR112023002573A2 - Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral - Google Patents
Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viralInfo
- Publication number
- BR112023002573A2 BR112023002573A2 BR112023002573A BR112023002573A BR112023002573A2 BR 112023002573 A2 BR112023002573 A2 BR 112023002573A2 BR 112023002573 A BR112023002573 A BR 112023002573A BR 112023002573 A BR112023002573 A BR 112023002573A BR 112023002573 A2 BR112023002573 A2 BR 112023002573A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prevention
- treatment
- pharmaceutical composition
- viral
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 108091005804 Peptidases Proteins 0.000 title abstract 2
- 239000004365 Protease Substances 0.000 title abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO OU PREVENÇÃO DE INFECÇÃO VIRAL E DISTÚRBIO RESPIRATÓRIO E MÉTODO DE INIBIÇÃO DE PROTEASE VIRAL. A presente invenção divulga compostos da Fórmula (I), e sais farmaceuticamente aceitáveis dos mesmos, que inibem a atividade de replicação do coronavírus. A invenção refere-se ainda a composições farmacêuticas que compreendem um composto da Fórmula (I) ou um sal farmaceuticamente aceitável do mesmo, e métodos de tratamento ou prevenção de uma infecção por coronavírus em um sujeito em necessidade, compreendendo a administração, ao sujeito, de uma quantidade terapeuticamente eficaz de um composto de Fórmula (I) ou de um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065283P | 2020-08-13 | 2020-08-13 | |
| PCT/US2021/045632 WO2022036018A1 (en) | 2020-08-13 | 2021-08-12 | Functionalized peptides as antiviral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002573A2 true BR112023002573A2 (pt) | 2023-03-14 |
Family
ID=80223910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002573A BR112023002573A2 (pt) | 2020-08-13 | 2021-08-12 | Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220048944A1 (pt) |
| EP (1) | EP4196117A1 (pt) |
| JP (1) | JP2023537402A (pt) |
| KR (1) | KR20230070207A (pt) |
| CN (1) | CN116547294A (pt) |
| AU (1) | AU2021324764A1 (pt) |
| BR (1) | BR112023002573A2 (pt) |
| CA (1) | CA3189248A1 (pt) |
| CO (1) | CO2023002852A2 (pt) |
| IL (1) | IL300589A (pt) |
| MX (1) | MX2023001756A (pt) |
| WO (1) | WO2022036018A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023005983A (es) | 2020-11-23 | 2023-08-15 | Enanta Pharm Inc | Nuevos agentes antivirales derivados de la espiropirrolidina. |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| CA3220847A1 (en) * | 2021-06-02 | 2022-12-08 | Long Mao | Protease inhibitors as antivirals |
| WO2022266363A1 (en) * | 2021-06-16 | 2022-12-22 | The Scripps Research Institute | Protease inhibitors for the treatment of coronavirus infections |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850003C (en) * | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| US11124497B1 (en) * | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
-
2021
- 2021-08-12 KR KR1020237008606A patent/KR20230070207A/ko unknown
- 2021-08-12 CN CN202180069618.1A patent/CN116547294A/zh active Pending
- 2021-08-12 EP EP21856680.0A patent/EP4196117A1/en active Pending
- 2021-08-12 WO PCT/US2021/045632 patent/WO2022036018A1/en active Application Filing
- 2021-08-12 BR BR112023002573A patent/BR112023002573A2/pt unknown
- 2021-08-12 IL IL300589A patent/IL300589A/en unknown
- 2021-08-12 AU AU2021324764A patent/AU2021324764A1/en active Pending
- 2021-08-12 US US17/400,190 patent/US20220048944A1/en not_active Abandoned
- 2021-08-12 CA CA3189248A patent/CA3189248A1/en active Pending
- 2021-08-12 JP JP2023509720A patent/JP2023537402A/ja active Pending
- 2021-08-12 MX MX2023001756A patent/MX2023001756A/es unknown
-
2023
- 2023-03-08 CO CONC2023/0002852A patent/CO2023002852A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001756A (es) | 2023-05-04 |
| EP4196117A1 (en) | 2023-06-21 |
| CN116547294A (zh) | 2023-08-04 |
| KR20230070207A (ko) | 2023-05-22 |
| CA3189248A1 (en) | 2022-02-17 |
| JP2023537402A (ja) | 2023-08-31 |
| AU2021324764A1 (en) | 2023-03-16 |
| WO2022036018A1 (en) | 2022-02-17 |
| IL300589A (en) | 2023-04-01 |
| CO2023002852A2 (es) | 2023-06-09 |
| US20220048944A1 (en) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026899A2 (pt) | Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório | |
| BR112023002573A2 (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral | |
| MY196455A (en) | Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection | |
| MX2023005984A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| BR112022025805A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir um distúrbio, condição ou doença | |
| MX2023005983A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| BR112022024476A2 (pt) | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 | |
| BR112022024450A2 (pt) | 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8 | |
| ZA202307575B (en) | Methods and modified nucleosides for treating coronavirus infections | |
| BR112022019557A2 (pt) | Inibidores de replicação de norovírus e coronavírus | |
| WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112020006381A8 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BR112022014861A2 (pt) | Métodos de tratamento para deficiência de alfa-1 antittripsina | |
| BR112022018067A2 (pt) | Aminas de pirrolopirimidina como inibidores de complemento | |
| BR112022017189A2 (pt) | Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1 | |
| BR112021018335A2 (pt) | Derivados de benzodiazepina como inibidores de rsv | |
| BR112021023347A2 (pt) | Compostos de pirrolidina | |
| MX2022012923A (es) | Inhibidores de trpc6 para tratar afecciones respiratorias. | |
| MX2022011490A (es) | Tratamiento o metodo de prevencion de falla cardiaca cronica. | |
| BR112023016970A2 (pt) | Compostos heterocíclicos antivirais | |
| BR112022018948A2 (pt) | Métodos de tratamento de lesão pulmonar com inibidores de cgrp | |
| MX2022011596A (es) | Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae. |